ReviewMalaria journal2016
Combating poor-quality anti-malarial medicines: a call to action.
Review in Malaria journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality.BMJ global health · 2020Pooled it
- Spectrophotometric analysis of artesunate injections available in community pharmacies in Northern and Western Uganda.Future science OA · 2025Article
- A 20-year evidence-based experience of the evolving medicine regulation in Zanzibar.Journal of pharmaceutical policy and practice · 2024Article
- A novel home-based method for preparing suspensions of anti-TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Prevalence of Poor Quality Ciprofloxacin and Metronidazole Tablets in Three Cities in Cameroon.The American journal of tropical medicine and hygiene · 2023Article
- Clinical needs assessment to inform development of a new assay to detect antimalarial drugs in patient samples: A case study.PLOS global public health · 2023Article
- Plasmodium manipulates the expression of host long non-coding RNA during red blood cell intracellular infection.Parasites & vectors · 2022Article
- Elusive quality: the challenges and ethical dilemmas faced by international non-governmental organisations in sourcing quality assured medical products.BMJ global health · 2021Review
- CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.Frontiers in genetics · 2021Review
- Optimizing the East African Community's Medicines Regulatory Harmonization initiative in 2020-2022: A Roadmap for the Future.PLoS medicine · 2020Review
- A new approach to an old problem: Overview of the East African Community's Medicines Regulatory Harmonization initiative.PLoS medicine · 2020Article
- Article
- Dynamic anti-counterfeiting security features using multicolor dianthryl sulfoxides.Chemical science · 2019Article
- Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.Pharmaceutics · 2019Review
- Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.Health policy and planning · 2019Article
- Prospects and strategies for malaria elimination in the Greater Mekong Sub-region: a qualitative study.Malaria journal · 2019Article
- Unintended Consequences and Hidden Obstacles in Medicine Access in Sub-Saharan Africa.Frontiers in public health · 2019Article
- Poor quality male latex condoms found in Dominican Republic: Quality assurance evaluation and public health impact.PloS one · 2019Article
- Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?BMC public health · 2018Article
- The Quality of Medicines Used in Children and Supplied by Private Pharmaceutical Wholesalers in Kinshasa, Democratic Republic of Congo: A Prospective Survey.The American journal of tropical medicine and hygiene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The circulation of poor-quality medicines continues to undermine the fight against many life-threatening diseases. Anti-malarial medicines appear to have been particularly compromised and present a major public health threat in malaria-endemic countries, negatively affecting individuals and their communities. Concerted collaborative efforts are required from global, regional and national organizations, involving the public and private sectors, to address the problem. While many initiatives are underway, a number of unmet needs deserve urgent and increased multisector attention. At the global level, there is a need for an international public health legal framework or treaty on poor-quality medicines, with statutes suitable for integration into national laws. In addition, increased international efforts are required to strengthen the governance of global supply chains and enhance cooperation between national medicine regulation authorities and law enforcement bodies. Increased investment is needed in innovative technologies that will enable healthcare teams to detect poor-quality medicines at all levels of the supply chain. At the regional level, a number of initiatives would be beneficial-key areas are standardization, simplification, and reciprocal recognition of registration processes and development of quality control capacity in regional centres of excellence that are better aligned with public health needs; improved surveillance methods and creation of a framework for compulsory and transparent reporting of poor-quality medicines; additional support for national medicine regulation authorities and other national partner authorities; and an increase in support for regional laboratories to boost their capabilities in detecting poor-quality medicines. It is vital that all stakeholders involved in efforts against poor-quality anti-malarial medicines extend and strengthen their actions in these critical areas and thus effectively support global health development and malaria elimination programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.